There is still only a very small number of pharmaceuticals that according to the relevant admission data contain nanomaterials. Among them are drugs for:

  • treatment of tumor diseases (e.g. Caelyx, Mepact, Abraxane, Rapamune, Renagel)
  • chronic hepatitis (e.g. PegIntron, Pegasys)
  • acromegaly (e.g. Somavert)
  • multiple sclerosis (e.g. Copaxone)
  • febrile neuropathy (e.g. Neulasta)
  • Morbus Crohn (e.g. Cimzia)
  • age-related macular degeneration (AMD) (e.g. Macugen)
  • increased LDL-C values and diabetes mellitus type 2 (e.g. Welchol)
  • MRT contrast agents (in-vivo diagnostics) with iron oxide nanoparticles (e.g. Feridex)
  • parenteral iron (e.g. Cosmofer, Ferrlecit)

Besides, several authors refer to drugs containing nanoscale molecules and particles:

  • liposomes (Caelyx, Myocet)
  • polymer-protein conjugates (PegIntron, Somavert)
  • polymeric substances (Copaxone)

Source : German Bundestag, Federal printed matter 17/3771.

 

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok